A new intranasal therapy (MP29-02*) is more effective than current firstline therapy regardless of season, symptom or severity.

Podobne knjige/članki

• A new allergic rhinitis therapy (MP29-02*) provides nasal and ocular symptom relief days faster than current firstline monotherapies
  od: Hellings, Peter, et al.
  Izdano: (2015)
• Short and long-term safety of MP29-02*: a new therapy for the treatment of allergic rhinitis
  od: Price, David, et al.
  Izdano: (2013)
• A new therapy (MP29-02*) effectively targets the entire seasonal allergic rhinitis symptom complex
  od: Price, David, et al.
  Izdano: (2013)
• A new therapy (MP29-02*) effectively controls nasal symptoms of seasonal allergic rhinitis irrespective of severity
  od: Scadding, Glenis, et al.
  Izdano: (2013)
• MP29-02*’s advanced delivery system contributes to its efficacy in patients with moderate/severe seasonal allergic rhinitis
  od: Scadding, Glenis, et al.
  Izdano: (2015)